ZBTB17/MIZ1 promotes peroxisome biogenesis by transcriptional regulation of PEX13
Journal of Cell Biology · 02.06.2025 · 224 (6)
DOI: 10.1083/jcb.202407198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Biology, online erschienen am 17.04.2025. Verfasst von Hongqin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, ShanghaiTech University , Shanghai, China. Hauptthemen laut MEDLINE: Peroxisomes, Membrane Proteins, Transcription, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University.
Abstract (Originalsprache)
Peroxisomes are integral metabolic organelles involved in both catabolic and anabolic processes in humans, with defects linked to diseases. The functions of peroxisomes are regulated at transcriptional, translational, and posttranslational levels. In this study, we employed the CRISPR/Cas9-based screening of a ubiquitin ligase library to identify regulators of human peroxisomes. We discovered that ZBTB17 (MIZ1) plays a role in regulating the import of proteins into peroxisomes. Independent of its ubiquitin ligase activity, ZBTB17/MIZ1 operates as a transcription factor to modulate the expression of key importer PEX13, influencing the localization of peroxisomal enzymes. Furthermore, metabolomic profiling reveals that knockdown of ZBTB17 or PEX13 results in similar metabolic alterations, with downregulated purine synthesis. Collectively, we identify ZBTB17 as a key regulator of peroxisomal protein import, thereby affecting peroxisomal function and nucleotide metabolism. Our findings provide insights into the multifaceted regulation of peroxisomes in complex human cells and shed light on the molecular mechanisms underlying ZBTB17’s role as a transcriptional regulator.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, ShanghaiTech University , Shanghai, China.
- University of Chinese Academy of Sciences , Beijing, China.
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences , Shanghai, China.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, China.
- State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Hongqin Liu, Xi Chen, Hanlin Wang, Guanglei Zhuang, Zheng-Jiang Zhu, Min Zhuang
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University
- Innovative Research Team of High-level Local Universities in Shanghai
- Shanghai Key Laboratory of Aging Studies
Zitieren
APA
Liu, H., Chen, X., Wang, H., Zhuang, G., Zhu, Z. J., & Zhuang, M. (2025). ZBTB17/MIZ1 promotes peroxisome biogenesis by transcriptional regulation of PEX13. Journal of Cell Biology, 224(6). https://doi.org/10.1083/jcb.202407198
Vancouver
Liu H, Chen X, Wang H, Zhuang G, Zhu ZJ, Zhuang M. ZBTB17/MIZ1 promotes peroxisome biogenesis by transcriptional regulation of PEX13. Journal of Cell Biology. 2025;224(6). doi:10.1083/jcb.202407198
BibTeX
@article{Liu2025,
author = {Liu, Hongqin and Chen, Xi and Wang, Hanlin and Zhuang, Guanglei and Zhu, Zheng-Jiang and Zhuang, Min},
title = {ZBTB17/MIZ1 promotes peroxisome biogenesis by transcriptional regulation of PEX13},
journal = {Journal of Cell Biology},
year = {2025},
volume = {224},
number = {6},
doi = {10.1083/jcb.202407198}
}
EUVIMED